EMA Tackles Tricky Business Of Defining Therapeutic Indications
Inconsistent Wording Makes Things Challenging For HTA Bodies And Payers
Executive Summary
The European Medicines Agency has identified key elements that regulatory reviewers should consider when evaluating the therapeutic indications proposed by companies.